MedPath

The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex

Not Applicable
Completed
Conditions
Healthy
Registration Number
NCT02891525
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

In this study, the investigators aimed at evaluating the role of sweet taste receptors in the gastrointestinal tract (GIT). Intragastric administration of glucose, fructose or acesulfame-K were compared with placebo administration for their effects on gastrointestinal motility, gut hormone release (motilin, ghrelin, glucagon-like peptide-1 (GLP-1) and insulin) and hunger feelings.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • BMI<30 kg/m² for the lean volunteers
  • Female or male subjects aged 18 to 60
  • Subject is capable and willing to give informed consent
  • Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception
Exclusion Criteria
  • Female volunteer is pregnant or breastfeeding
  • GI diseases, major abdominal surgery
  • Volunteers that have food allergies, especially fructose intolerance
  • Major psychiatric illnesses
  • Volunteers that use drugs affecting the GI tract or the central nervous system
  • Volunteers suffering from an endocrine disease such as diabetes, Cushing's disease, Addison's disease, hypothalamic tumor
  • Volunteers that have undergone surgical procedure for weight loss

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Change in gastrointestinal motility measured by antroduodenal high-resolution manometry3 hours after administration, continuous measurement with high resolution manometry
Secondary Outcome Measures
NameTimeMethod
Change in gut hormone release measured by specific radioactive immunoassays3 hours after administration, blood sample every 15 min
Change in subjective hunger and satiety scores measured by visual analogue scales of 100 mm3 hours after administration, assessment every 5 min

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.